Bernstein, This is why we have been trying to warn you about this stock. I for one have lost everything! This stock has ruined me. while you would expect it to run on news of submission of Rexista, DO NOT COUNT ON IT. the last time they originally submitted we saw no price appreciation. The reason given it was already price in as a known catalyst. Everyone knows they intend to refile, so why would it jump up?
As for being in 4 weeks, one could also argue it should be within the next week! They originally, stated that they wanted to refile in October or November. Then they changed that to "by year end" so does that mean still the end of fiscal year which would be the end of November or do they now push it back to December?
One has to ask, why can't they ever meet anything they say they are going to do? if one looks back at the January update they didn't meet one thing they said they were going to do.
Had they started the HAP studies when they said they wanted too, we would not still be waiting on the results by fiscal year end! Had they done the Podras trials and released those results we may have not needed to Reverse split. Had they Partnered Regabatin we would not needed to RS. had they refiled in September, as they stated in the update, they would not needed to RS or at least would not needed to complete a toxic dilution. Yet, they did succeed in spending 13 million dollars! on what? The October capital raise in 2017 was high and they said it was for raising monies to pay for the studies. so just what did they spend 13 million on this year and we have 0. absolutely 0 to show for it!
so please, do not be as foolish as I was. Look at these signs. Do not count on anything.
